TMUS touched the $18 level last week. We are holding some position in TMUS until the market can place a modest value on the new company. WOW did the May and June $17 and $18 call volume open up. I don't think we have come near the top on TMUS, but we have to find something other than just a traditional fundamental analysis value on this new and explosive company. What will the market bear on this one?
AAMRQ is one of my old favorites and is continuing it's march up above $4. It closed up for another nice gain last week.
Competitive Technologies, (OTCQB:CTTC), distributor of a non-narcotic and non-invasive medical device for the treatment of chronic pain, may be entering a "Perfect Storm" of media exposure and corporate developments in the next few weeks. The American Society of Clinical Oncology (ASCO) has an upcoming Annual meeting where promising technologies and biopharmaceutical advances are presented to the cancer medical community. These presentations can have a dramatic effect on the share prices of publicly-held companies to the degree that the SEC has asked ASCO to enforce a news embargo until May 15, when all presentations on the schedule for the ASCO meeting are posted on the ASCO website. CTTC's Calmare medical device has been in clinical studies with the Mayo Clinic, University of Wisconsin and Virginia Commonwealth University. And all three institutions are expected to release their patient data very soon. There is no guarantee that Calmare will be the subject of a presentation at the ASCO meeting, but there is speculation that at least one of the three institutions will be highlighting Calmare and its effects on chronic pain patients suffering from neuropathic pain. With only 16.4 Million shares outstanding, a recent price of $0.30 and considering the details--including TV news videos-- in the CTTC Research Report available here, CTTC is one to watch for potential gains in May.